PK and PD of peginterferon beta‐1a in multiple sclerosis patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|79|3|514-522

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.79, Iss.3, 2015-03, pp. : 514-522

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Exacerbation of Darier disease by peg‐interferon beta‐1a in a patient suffering from multiple sclerosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 57, Iss. 1, 2018-01 ,pp. : 116-117

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

By Castelli-Haley Jane  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 830-830

Springer Publishing Company

Access to resources Recommend Favorite

Interferon beta‐1b‐induced Sweet's syndrome in a patient with multiple sclerosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 4, 2015-04 ,pp. : 456-458

John Wiley & Sons Inc

Access to resources Recommend Favorite

Antibodies to Commercially Available Interferon–Beta Molecules in Multiple Sclerosis Patients Treated with Natural Interferon–Beta

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 368-371

Karger

Access to resources Recommend Favorite

Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon‐beta 1a: Case Report

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : e140-e145

John Wiley & Sons Inc

Access to resources Recommend Favorite